All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-07-26T11:36:09.000Z

Ponatinib plus chemotherapy and allo-HSCT in newly diagnosed Ph+ ALL: Final results from the PONALFIL trial

Jul 26, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL


The phase II PONALFIL trial (NCT02776605) from the Programa Español de Tratamientos en Hematología (PETHEMA) group assessed the safety and efficacy of ponatinib in combination with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) with pre-emptive ponatinib after allo-HSCT in 30 adult patients with newly diagnosed (ND) Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).1 The ALL Hub previously reported the initial results from this trial. Below, we summarize the final results from this trial, with a median follow-up of 4 years, presented by Ribera during the European Hematology Association (EHA) 2024 Hybrid Congress.1  

Key learnings
The complete molecular response rates post-induction (n = 30), post-consolidation (n = 28), and post-allo-HSCT (n = 26) were 47%, 71%, and 100%, respectively. 
The 4-year overall survival (OS) and event-free survival rates were 92% and 66%, respectively, with no differences according to BCR-ABL1 isoform. 
Overall, six patients relapsed after the transplant and were successfully managed with ponatinib, chemotherapy, and CAR T-cell therapy or a second allo-HSCT. 

A propensity-score comparison between the PONALFIL trial and the PhALL08 trial (NCT01491763), which used imatinib, showed that the PONALFIL cohort had:  

  • higher complete remission (CR) rates (100% vs 93%, respectively) and estimated 5-year OS (92% vs 43%, respectively); and  

  • lower morphological relapse (10% vs 21%, respectively) and death in CR rates (6% vs 25%, respectively). 

These final results from the PONALFIL trial confirm the efficacy of ponatinib in combination with standard induction and consolidation chemotherapy followed by allo-HSCT and further support the use of this regimen as a first-line therapy for adult patients with newly diagnosed Ph+ ALL. 


  1. Ribera JM. Ponatinib, chemotherapy and transplantation for newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Final results of the phase 2 PONALFIL trial. Poster #P398. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16, 2024; Madrid, ES.   

Your opinion matters

Which of the following treatment options would you prefer to use directly before CD19-directed CAR T-cell therapy in adult patients with Ph− R/R B-cell ALL?
2 votes - 4 days left ...

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox